A detailed history of Legal & General Group PLC transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 6,650 shares of KALV stock, worth $63,108. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,650
Previous 6,650 -0.0%
Holding current value
$63,108
Previous $77,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$9.46 - $15.39 $2,554 - $4,155
270 Added 4.23%
6,650 $77,000
Q2 2024

Aug 14, 2024

BUY
$10.35 - $12.49 $39,164 - $47,262
3,784 Added 145.76%
6,380 $75,000
Q4 2023

Feb 15, 2024

BUY
$7.58 - $12.25 $4,881 - $7,889
644 Added 32.99%
2,596 $31,000
Q3 2023

Nov 14, 2023

SELL
$8.95 - $11.35 $3,624 - $4,596
-405 Reduced 17.18%
1,952 $18,000
Q3 2022

Nov 14, 2022

BUY
$9.85 - $16.83 $2,994 - $5,116
304 Added 14.81%
2,357 $34,000
Q2 2022

Aug 22, 2022

SELL
$8.16 - $15.1 $5,875 - $10,872
-720 Reduced 25.96%
2,053 $20,000
Q4 2021

Feb 14, 2022

BUY
$12.36 - $18.28 $3,967 - $5,867
321 Added 13.09%
2,773 $37,000
Q2 2021

Aug 12, 2021

BUY
$23.12 - $29.91 $18,172 - $23,509
786 Added 47.18%
2,452 $59,000
Q1 2021

May 17, 2021

BUY
$14.69 - $42.57 $5,112 - $14,814
348 Added 26.4%
1,666 $43,000
Q3 2020

Nov 13, 2020

SELL
$9.83 - $13.99 $4,108 - $5,847
-418 Reduced 24.08%
1,318 $17,000
Q2 2020

Aug 14, 2020

SELL
$6.75 - $12.89 $2,450 - $4,679
-363 Reduced 17.29%
1,736 $21,000
Q1 2020

May 14, 2020

SELL
$5.8 - $18.56 $1,873 - $5,994
-323 Reduced 13.34%
2,099 $16,000
Q4 2019

Feb 13, 2020

BUY
$10.31 - $17.81 $4,928 - $8,513
478 Added 24.59%
2,422 $40,000
Q2 2019

Aug 14, 2019

BUY
$18.44 - $30.89 $35,847 - $60,050
1,944 New
1,944 $43,000

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $233M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.